Working to right the ship, BridgeBio's Neil Kumar adds a $110M deal right on top of his cash haul from Bristol Myers
Within hours of issuing word that BridgeBio $BBIO had pulled in $90 million from its SHP2 licensing deal with Bristol Myers Squibb, CEO Neil Kumar had finalized another deal to sell their priority review voucher for $110 million.
Not unusual in PRV sales, the biotech is keeping the purchaser’s name under wraps, but Kumar — who’s been restructuring the company, partnering programs, laying off staffers and looking to do deals to keep the ship righted during a stormy biotech tempest on Wall Street — was more than happy to discuss the latest windfall to come his way “at a really attractive price.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.